Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials.
暂无分享,去创建一个
[1] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[2] G. Stone,et al. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. , 2016, Journal of the American College of Cardiology.
[3] P. Jüni,et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[4] Sunil V. Rao,et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial , 2015, The Lancet.
[5] G. Stone,et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.
[6] B. Gersh,et al. Do current clinical trials meet society's needs?: a critical review of recent evidence. , 2014, Journal of the American College of Cardiology.
[7] E. Omerovic,et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. , 2014, The New England journal of medicine.
[8] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[9] S. Kaul. Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.
[10] P. Kolh,et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis , 2014, BMJ : British Medical Journal.
[11] Maurice Buchbinder,et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.
[12] Tim Friede,et al. Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data , 2014, Pharmaceutical statistics.
[13] Deepak L. Bhatt,et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.
[14] N. Simon,et al. Adaptive enrichment designs for clinical trials. , 2013, Biostatistics.
[15] Gregg W Stone,et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.
[16] Akshay S. Desai,et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. , 2013, The New England journal of medicine.
[17] G. Guyatt,et al. How to use a noninferiority trial: users' guides to the medical literature. , 2012, JAMA.
[18] J. McMurray,et al. When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches , 2012, Circulation. Heart failure.
[19] S. Pocock,et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.
[20] T. Huber,et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients , 2012 .
[21] D. Atar,et al. Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.
[22] Cyrus R Mehta,et al. Adaptive increase in sample size when interim results are promising: A practical guide with examples , 2011, Statistics in medicine.
[23] F. Harrell,et al. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. , 2011, American heart journal.
[24] Deepak L. Bhatt,et al. Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.
[25] Á. Chamorro,et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial , 2011, The Lancet.
[26] Stuart J Pocock,et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.
[27] Deepak L. Bhatt,et al. APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* , 2011 .
[28] S. Werns. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes , 2011 .
[29] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[30] S. Yusuf,et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. , 2010, The New England journal of medicine.
[31] Draft Guidance. Guidance for Industry Non-Inferiority Clinical Trials , 2010 .
[32] Draft Guidance. Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .
[33] Gregg W Stone,et al. Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.
[34] B. Gersh,et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. , 2009, The New England journal of medicine.
[35] S. Connolly,et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.
[36] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[37] J. Lachin. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit , 2009, Clinical trials.
[38] Cyrus Mehta,et al. Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.
[39] K. Bailey,et al. From randomized trials to registry studies: translating data into clinical information , 2008, Nature Clinical Practice Cardiovascular Medicine.
[40] R. Ferrari,et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[41] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[42] Shein-Chung Chow,et al. Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.
[43] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[44] D. Berman,et al. Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.
[45] Stuart J Pocock,et al. Current controversies in data monitoring for clinical trials , 2006, Clinical trials.
[46] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[47] M. Krams,et al. Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.
[48] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[49] Sydes,et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.
[50] Alan A Montgomery,et al. Design, analysis and presentation of factorial randomised controlled trials , 2003, BMC medical research methodology.
[51] D. Stryer,et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.
[52] G. Stone,et al. Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.
[53] Peter Sleight,et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.
[54] David L. DeMets,et al. Data Monitoring Committees in Clinical Trials: A Practical Perspective , 2002 .
[55] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[56] Giuseppe Mancia,et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.
[57] S J Pocock,et al. Randomized trials or observational tribulations? , 2000, The New England journal of medicine.
[58] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[59] S. Yusuf,et al. Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.
[60] S. Yusuf,et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .
[61] D. DeMets,et al. The agonising negative trend in monitoring of clinical trials , 1999, The Lancet.
[62] W F Rosenberger,et al. Randomized play-the-winner clinical trials: review and recommendations. , 1999, Controlled clinical trials.
[63] J. Ware,et al. Equivalence trials. , 1997, The New England journal of medicine.
[64] Raymond C. Schneider,et al. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.
[65] S. Pocock,et al. Factorial trials in cardiology: pros and cons. , 1994, European heart journal.